Precision BioSciences, Inc. (DTIL)

Over the past six months, Precision BioSciences' stock price has been impacted by several events. The company reported a significant earnings miss in Q3 2025, contributing to negative pressure on the stock. The stock has declined over 31% in the past year, trading near its 52-week low in January 2026, attributed to biotech sector weakness and investor concerns. The company received FDA Orphan Drug Designation for PBGENE-DMD in August 2025, which could have provided some upward momentum. In January 2026, the company announced progress in its Phase 1/2a ELIMINATE-B trial for chronic hepatitis B and regulatory clearance for the PBGENE-DMD program is anticipated in Q1 2026. In Q4 2025, Precision BioSciences received an $8 million milestone payment related to Imugene's progress with azer-cel. Positive news from licensee iECURE in January 2026 led to a temporary increase in Precision BioSciences' shares. In January 2026, Precision BioSciences set strategic priorities focused on the continued advancement of its clinical-stage programs PBGENE-HBV and PBGENE-DMD. A 1-30 reverse stock split occurred on Wednesday, February 14, 2024, which would have significantly impacted the share price and number of shares outstanding.

Information regarding demand seasonality for Precision BioSciences, Inc.'s products and services is limited due to its nature as a clinical-stage biotechnology company. An analysis of DTIL's stock price seasonality over the past five years suggests a "Buy Date" of October 20 and a "Sell Date" of January 10, resulting in a geometric average return of 15.34% above the S&P 500 Total Return Index. This seasonal timeframe correlates poorly with the broader Healthcare sector's seasonal strength, indicating that any observed stock seasonality for DTIL may not be directly tied to the demand for its specific products or services.

Precision BioSciences, Inc. is a clinical-stage biotechnology company focused on improving life through its ARCUS® genome editing platform. The company operates in the Healthcare sector, specifically in the Biotechnology and Medical - Biomedical and Genetics industries. It develops in vivo gene editing therapies for various conditions using its ARCUS platform for precise DNA manipulation. Major products and programs include PBGENE-HBV for chronic hepatitis B virus, PBGENE-DMD for Duchenne muscular dystrophy, immuno-oncology programs including allogeneic CAR T treatments, programs targeting mitochondrial disorders and rare genetic conditions, and food segment applications through collaborations. The company also has collaboration agreements with partners such as Novartis Pharma AG and iECURE, Inc.

Precision BioSciences, Inc. primarily operates and develops its therapeutic products in the United States and is headquartered in Durham, North Carolina.

Precision BioSciences' brand reputation appears to be a mix of cautious optimism and ongoing challenges. The company has received a consensus rating of "Hold" from analysts, with some analysts having a "Strong Buy" rating. Positive developments in clinical trials and collaborations contribute positively to its scientific and developmental reputation. Financial performance concerns, including missing analyst expectations and declining revenue, negatively impact investor confidence. The company is also quickly burning through cash.

Precision BioSciences, Inc. has a diverse ownership structure. Institutional owners and shareholders hold approximately 23% of the company's shares, with major holders including Bleichroeder LP, Lynx1 Capital Management LP, and Vanguard Group Inc. Retail investors are the largest shareholders, holding 27% ownership of the company. Insiders collectively own 0.9% of the company's shares, with CEO Michael Amoroso owning 0.9%.